Background: Although inhaled nitric oxide (iNO) therapy in term infants with pulmonary hypertension (PHT) has demonstrated definite benefit, the use of iNO in preterm infants remains inconclusive.
Aims: To evaluate the impact of iNO treatment in premature infants with acute PHT.
Study Design: Retrospective cohort.
Subjects: Infants < 34 weeks' gestational age, admitted during 2010-2016 to two neonatal units, having treated with iNO for confirmed PHT. A positive response was defined by FiO reduction ≥20% within 3-h post iNO initiation. Early PHT was defined when developed within the first 72 h of age.
Outcome Measures: The primary outcome was the evaluation of the acute response to iNO administration. Secondary outcomes included the comparison of neonatal characteristics and outcomes between positive and negative responders, and early or late PHT infants.
Results: Of the 55 infants of our cohort, 39 (71%) had a positive response to iNO administration. No differences noted regarding bronchopulmonary dysplasia, intraventricular haemorrhage or other morbidities; however, positive responders had significantly higher survival rate in overall (77 vs 21%, p = 0.001) and within early PHT subgroup (74 vs 33%, p = 0.044). Regression analysis revealed that oligohydramnios (OR 2.834, 95%CI 1.652-6.070) and early PHT (OR 1.953, 95%CI 1.377-2.930) were significantly related with a positive response.
Conclusions: Preterm infants with confirmed acute PHT respond in significant proportion to the iNO administration, especially in the background of oligohydramnios or the development of early PHT.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.earlhumdev.2018.09.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Oxidative and nitrative DNA damage induced by industrial chemicals in relation to carcinogenesis.
J Occup Health
January 2025
Department of Environmental Health, University of Fukui School of Medical Science, Eiheiji, Fukui, Japan.
Objectives: Many chemicals have been used for industrial purposes, and some of them are carcinogenic to humans. However, their molecular mechanisms have not been well understood. Reactive oxygen species are generated from industrial chemicals and contribute to carcinogenesis.
View Article and Find Full Text PDFUse, Benefits, and Adverse Effects of Inhaled Nitric Oxide During Anesthesia.
Ann Card Anaesth
January 2025
Department of Surgery, Division of Anesthesiology, Hospital das Clínicas de Belo Horizonte, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Inhaled corticosteroids in asthma and chronic obstructive pulmonary disease combined phenotype: when to use and what to expect?
Monaldi Arch Chest Dis
January 2025
Department of Community Medicine, K.S. Hegde Medical College, Deralakatte, Karnataka.
The term "asthma-chronic obstructive pulmonary disease (COPD) combined phenotype" describes patients with persistent airflow limitation and features of both asthma and COPD. There is a lack of data on effective treatments for this group, often excluded from asthma or COPD trials. Inhaled corticosteroids (ICS) are standard for asthma, while bronchodilators are key for COPD.
View Article and Find Full Text PDFBiologics as well as inhaled anti-asthmatic therapy achieve clinical remission: Evidence from the Severe Asthma Network in Italy (SANI).
World Allergy Organ J
January 2025
Department of Statistics and Quantitative Methods, University of Milano-Bicocca, Milan, Italy.
Background: This study aimed to evaluate the impact of severe asthma (SA) treatments after 12 months in achieving clinical remission (CR) within the context of the Severe Asthma Network in Italy (SANI) using the recent SANI definition of CR on treatment.
Methods: CR has been defined by SANI as complete, partial, and no CR. Complete CR is defined by the absence of oral corticosteroids (OCS), no symptoms, no exacerbations, and stable lung function, and partial CR requires the absence of OCS and the fulfillment of 2 out of the other 3 criteria.
The effect of inhaled nitric oxide treatment on biomarkers of oxidative/nitrosative damage to proteins and DNA/RNA.
Free Radic Biol Med
January 2025
Neonatal Research Group, Health Research Institute Hospital La Fe (IISLAFE), Avda Fernando Abril Martorell 106, 46026, Valencia, Spain; Spanish Network in Maternal, Neonatal, Child and Developmental Health Research (RICORS SAMID) (RD24/0013/0014), Instituto de Salud Carlos III, Madrid, Spain; Division of Neonatology, University & Polytechnic Hospital La Fe, Avda Fernando Abril Martorell 106, 46026, Valencia, Spain. Electronic address:
Inhaled nitric oxide (iNO) is a selective pulmonary vasodilator that is used as a treatment for persistent pulmonary hypertension in neonates (PPHN) with hypoxic respiratory failure. The generation of reactive oxygen and nitrogen species might induce oxidative/nitrosative damage to multiple organs. There is an increasing scientific and clinical interest in the determination of specific biomarkers to measure the degree of oxidative/nitrosative stress in non-invasively collected biofluids.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!